Lipoxins Inhibit Akt/PKB Activation and Cell Cycle Progression in Human Mesangial Cells

American Journal of Pathology

Volumn 164, Issue 3, 2004, Pages 937-946

  Mitchell, Derick ^a,b,c   Rodgers, Karen ^a,b,c   Hanly, Jennifer ^a,b,c   McMahon, Blaithin ^a,b,c   Brady, Hugh R ^a,b,c   Martin, Finian ^b,c   Godson, Catherine ^a,b,c  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c Dublin Molecular Medicine Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

15 METHYLLIPOXIN A4; 16 PHENOXYLIPOXIN A4; LIPOXIN; LIPOXIN A; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; ENZYME ACTIVITY; GENE ACTIVATION; GLOMERULUS; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; KIDNEY FIBROSIS; MESANGIUM CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 1242271333     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63181-1     Document Type: Article

References (44)

1. McMahon BM, Mitchell S, Brady HR, Godson C: Lipoxins: revelations on resolution. Trends Pharmacol Sci 2001, 22:391-395
2. Serhan CN: Lipoxins and novel aspirin-triggered 15-epilipoxins[ATL]: a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 1997, 53:107-137
3. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat Med 2001, 2:612-619
4. Papayianni A, Serhan CN, Phillips ML, Rennke HG, Brady HR: Transcellular biosynthesis of lipoxir, A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int 1995, 1295-1302
5. Mayadas TN, Mendrick DL, Brady HR, Tang T, Papayianni A, Assmann KJ, Wagner DD, Hynes RO, Cotran RS: Acute passive antiglomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int 1996, 49:1342-1349
6. Clish CB, O'Brien JA, Gronert K, Stahl GL, Petasis NA, Serhan CN: Local and systemic delivery of an aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci USA 1999, 96:8247-8252
7. Abboud HE: Growth factors in glomerulonephritis. Kidney Int 1993, 43:252-267
8. Silver BJ, Jaffer FE, Abboud HE: Platelet-derived growth factor synthesis in mesangial cells: induction by multiple growth factors. Proc Natl Acad Sci 1989, 86:1056-1060
9. McMahon B, Stenson C, McPhillips F, Fanning A, Brady HR and Godson C: Lipoxin A4 antagonises the mitogenic effect of LTD4 on human renal mesangial cells: differential activation of MAP kinases through distinct receptors. J Biol Chem 2000, 275:27566-27575
10. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992, 175:1413-1416
11. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic N: Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis byaptamers. Am J Pathol 1999, 154:169-179
12. Ostendorf T, van Roeyen CR, Peterson JD, Kunter U, Eitner F, Hamad AJ, Chan G, Jia XC, Macaluso J, Gazit-Bornstein G, Keyt BA, Lichenstein HS, LaRochelle WJ, Floege J: A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2003, 14:2237-2247
13. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001, 59:1324-1332
14. Floege J, Johnson RJ: Multiple roles for platelet-derived growth factor in renal disease. Minor Electrolyte Metab 1995, 21:271-282
15. Heldin H, Ostmann A, Ronnstrand L: Signal transduction via platelet-derived growth factor receptors. Biochim Biophysica Acta 1998, 1378:F79-F113
16. McMahon B, Mitchell D, Shattock R, Martin F, Brady HR, Godson C: Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. EMBO J 2002, 16:1817-1819
17. Mene P: Mesangial cell cultures. J Nephrol 2001, 14:198-203
18. Goppelt-Struebe M, Fickel S, Reiser CO: The platelet-derived-growth-factor receptor, not the epidermal-growth-factor receptor, is used by lysophosphatidic acid to activate p42/44 mitogen-activated protein kinase and to induce prostaglandin G/H synthase-2 in mesangial cells. Biochem J 2000, 345:217-224
19. Grewal JS, Luttrell LM, Raymond JR: G protein-coupled receptors desensitize and downregulate EGF receptors in renal mesangial cells. J Biol Chem 2001, 276:27335-27344
20. Nebigil CG, Garnovskaya MN, Spurney RF, Raymond JR: Identification of a rat glomerular mesangial cell mitogenic 5-HT2A receptor. Am J Physiol 1995, 268: F122-F127
21. Ghosh-Choudhury G, Zhang JH, Ghosh-Choudhury N, Abboud HE: Ceramide blocks PDGF-induced DNA synthesis in mesangial cells via inhibition of Akt kinase in the absence of apoptosis. Biochim Biophys Res Commun 2001, 286:1183-1190
22. Schoecklmann HO, Rupprecht HD, Zauner I, Sterzel RB: TGF 1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation. Kidney Int 1997, 51:1228-1236
23. Shankland SJ, Pippin J, Flanagan M, Coats SR, Nangaku M, Gordon KL, Roberts JM, Couser WG, Johnson RJ: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27 Kip1. Kidney Int 1997, 51:1088-1099
24. Sherr CJ: G1 phase progression: cycling on cue. Cell 1994, 79:551-555
25. Yamabe H, Osawa H, Kaizuka M, Tsunoda S, Shirato K, Tateyama F, Okumura K: Platelet-derived growth factor, basic fibroblast growth factor, and interferon γ increase type IV collagen production in human fetal mesangial cells via a transforming growth factor-β-dependent mechanism. Nephrol Dial Transpl 2000, 15:872-876
26. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999, 274:5830-5834
27. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL: PKB/Akt mediates cell-cycle progression by phosphorylation of p27 Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002, 8:1145-1152
28. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002, 8:1153-1160
29. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27 (Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002, 8:1161-1165
30. Presig PA, Franch HA: Renal epithelial hyperplasia and hypertrophy. Semin Nephrol 1995, 15:327-340
31. Sherr CJ: Mammalian G1 cyclins. Cell 1993, 73:1059-1065
32. Morgan DO: principles of CDK regulation. Nature 1995, 374:131-134
33. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev 1995, 9:1149-1163
34. Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC, Walsh K, Fiore S, Koch AE, Firestein GS, Haines III KG, Pope RM: IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 2003, 170:838-845
35. Shankland SJ, Hugo C, Coats SR, Nangaku M, Pichler RH, Gordon KL, Pippin J, Roberts JM, Couser WG, Johnson RJ: Changes in cell cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int 1996, 50:1230-1239
36. Franke TF, Kaplan DR, Cantley LC, Toker A: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science 1997, 275:665-668
37. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001, 3:973-982
38. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999, 13:1181-1189
39. Ghosh Choudhury G, Lenin M, Calhaun C, Zhang JH, Abboud HE: PDGF inactivates forkhead family transcription factor by activation of Akt in glomerular mesangial cells. Cell Signal 2002, 15:161-70
40. Shankland SJ: Cell-cycle control and renal disease. Kidney Int 1997, 52:294-308
41. Monkawa T, Hiromura K, Wolf W, Shankland SJ: The hypertrophic effecl of transforming growth factor b is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27. J Am Soc Nephrol 2002, 13:1172-1178
42. Colville-Nash PR, Gilroy DW: Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. BioDrugs 2001, 15:1-9
43. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, Petasis NA, Erwig L, Rees AJ, Savill J, Brady HR, Godson C: Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 2002, 13:2497-2507
44. Serhan CN: Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 2002, 68-69:433-455